Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus

Published:2016-12 Issue:11 Volume:118 Page:1774-1780
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Tang Huilin,Fang Zhenwei,Wang Tiansheng,Cui Wei,Zhai Suodi,Song Yiqing

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Glucose control by the kidney: an emerging target in diabetes;Marsenic;Am J Kidney Dis,2009

2. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis;Vasilakou;Ann Intern Med,2013

3. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs;Hirshberg;Diabetes Care,2011

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

5. The EMPA-REG study: what has it told us? A diabetologist's perspective;DeFronzo;J Diabetes Complications,2016

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity;Scientific Reports;2024-05-11

2. Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction;Obesity Facts;2024

3. The effect of SGLT2 inhibitor on clinical outcomes in patients with type 2 diabetes and atrial fibrillation;2023-12-21

4. Effects of 3-month dapagliflozin on left atrial function in treatment-naïve patients with type 2 diabetes mellitus: Assessment using 4-dimensional echocardiography;Hellenic Journal of Cardiology;2023-12

5. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with Obesity;2023-11-15